Cargando…

Dual-targeting cyclic peptides of receptor-binding domain (RBD) and main protease (Mpro) as potential drug leads for the treatment of SARS-CoV-2 infection

The receptor-binding domain (RBD) and the main protease (Mpro) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) play a crucial role in the entry and replication of viral particles, and co-targeting both of them could be an attractive approach for the treatment of SARS-CoV-2 infection...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Zhen, Zou, Yunting, Gao, Xi, Niu, Miao-Miao, Li, Jindong, Xue, Lu, Jiang, Su
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9627161/ https://www.ncbi.nlm.nih.gov/pubmed/36339564 http://dx.doi.org/10.3389/fphar.2022.1041331

Ejemplares similares

Non-covalent cyclic peptides simultaneously targeting Mpro and NRP1 are highly effective against Omicron BA.2.75
por: Yin, Shengnan, et al.
Publicado: (2022)

Discovery of dual S-RBD/NRP1-targeting peptides: structure-based virtual screening, synthesis, biological evaluation, and molecular dynamics simulation studies
por: Hu, Chunfang, et al.
Publicado: (2023)

Recognition of Natural Products as Potential Inhibitors of COVID-19 Main Protease (Mpro): In-Silico Evidences
por: Narkhede, Rohan R., et al.
Publicado: (2020)

Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors
por: Amin, Sk. Abdul, et al.
Publicado: (2021)

Potential Resistance of SARS-CoV-2 Main Protease (Mpro) against Protease Inhibitors: Lessons Learned from HIV-1 Protease
por: Mótyán, János András, et al.
Publicado: (2022)

Computational Simulation of HIV Protease Inhibitors to the Main Protease (Mpro) of SARS-CoV-2: Implications for COVID-19 Drugs Design
por: Yu, Wei, et al.
Publicado: (2021)

Structural and Biochemical Analysis of the Dual Inhibition of MG-132 against SARS-CoV-2 Main Protease (Mpro/3CLpro) and Human Cathepsin-L
por: Costanzi, Elisa, et al.
Publicado: (2021)

Coagulation modifiers targeting SARS-CoV-2 main protease Mpro for COVID-19 treatment: an in silico approach
por: Biembengut, Ísis Venturi, et al.
Publicado: (2020)

A cyclic peptide inhibitor of the SARS-CoV-2 main protease
por: Kreutzer, Adam G., et al.
Publicado: (2021)

Antiviral cyclic peptides targeting the main protease of SARS-CoV-2
por: Johansen-Leete, Jason, et al.
Publicado: (2022)

Structure-based screening of novel lichen compounds against SARS Coronavirus main protease (Mpro) as potentials inhibitors of COVID-19
por: Joshi, Tanuja, et al.
Publicado: (2020)

Discovery of novel inhibitors against main protease (Mpro) of SARS-CoV-2 via virtual screening and biochemical evaluation
por: Guo, Sheng, et al.
Publicado: (2021)

Investigation of structural analogs of hydroxychloroquine for SARS-CoV-2 main protease (Mpro): A computational drug discovery study
por: Reyaz, Saima, et al.
Publicado: (2021)

A VSV-based assay quantifies coronavirus Mpro/3CLpro/Nsp5 main protease activity and chemical inhibition
por: Heilmann, Emmanuel, et al.
Publicado: (2022)

Finding potential inhibitors for Main protease (Mpro) of SARS-CoV-2 through virtual screening and MD simulation studies
por: Ahamed, N. Anis, et al.
Publicado: (2023)

E3 ubiquitin ligase ZBTB25 suppresses beta coronavirus infection through ubiquitination of the main viral protease MPro
por: Lear, Travis B., et al.
Publicado: (2023)

Molecular modeling and simulations of some antiviral drugs, benzylisoquinoline alkaloid, and coumarin molecules to investigate the effects on Mpro main viral protease inhibition
por: Mir, Showkat Ahmad, et al.
Publicado: (2023)

Discovery of potent and noncovalent KRAS(G12D) inhibitors: Structure-based virtual screening and biological evaluation
por: Wang, Yuting, et al.
Publicado: (2022)

Dietary polyphenols mitigate SARS-CoV-2 main protease (Mpro)–Molecular dynamics, molecular mechanics, and density functional theory investigations
por: Adelusi, Temitope Isaac, et al.
Publicado: (2022)

Identification of SARS-CoV-2 Main Protease (Mpro) Cleavage Sites Using Two-Dimensional Electrophoresis and In Silico Cleavage Site Prediction
por: Miltner, Noémi, et al.
Publicado: (2023)

Synthesis, Molecular Docking, and Dynamic Simulation Targeting Main Protease (Mpro) of New, Thiazole Clubbed Pyridine Scaffolds as Potential COVID-19 Inhibitors
por: Alghamdi, Adel, et al.
Publicado: (2023)

Tyrosine Phosphorylation of Botulinum Neurotoxin Protease Domains
por: Toth, Stephen, et al.
Publicado: (2012)

Evaluation of Xa inhibitors as potential inhibitors of the SARS-CoV-2 Mpro protease
por: Papaj, Katarzyna, et al.
Publicado: (2022)

Novel antiviral effects of chloroquine, hydroxychloroquine, and green tea catechins against SARS CoV-2 main protease (Mpro) and 3C-like protease for COVID-19 treatment
por: Shaik, Fareeda Begum, et al.
Publicado: (2022)

First structure–activity relationship analysis of SARS-CoV-2 virus main protease (Mpro) inhibitors: an endeavor on COVID-19 drug discovery
por: Amin, Sk. Abdul, et al.
Publicado: (2021)

Targeting omicron and other reported SARS-CoV-2 lineages by potent inhibitors of main protease 3CL Mpro: Molecular simulation analysis
por: Saeed, Aamir, et al.
Publicado: (2022)

Garbage in, garbage out: how reliable training data improved a virtual screening approach against SARS-CoV-2 MPro
por: Ruatta, Santiago M., et al.
Publicado: (2023)

A GSH/CB Dual-Controlled Self-Assembled Nanomedicine for High-Efficacy Doxorubicin-Resistant Breast Cancer Therapy
por: Yang, Yang, et al.
Publicado: (2022)

Drug Repurposing and Polypharmacology to Fight SARS-CoV-2 Through Inhibition of the Main Protease
por: Pinzi, Luca, et al.
Publicado: (2021)

QSAR and molecular docking studies on designing potent inhibitors of SARS-CoVs main protease
por: Song, Fucheng, et al.
Publicado: (2023)

Flavonoid glycosides and their putative human metabolites as potential inhibitors of the SARS-CoV-2 main protease (Mpro) and RNA-dependent RNA polymerase (RdRp)
por: da Silva, Felipe Moura A, et al.
Publicado: (2020)

Identification of bioactive molecules from Triphala (Ayurvedic herbal formulation) as potential inhibitors of SARS-CoV-2 main protease (Mpro) through computational investigations
por: Rudrapal, Mithun, et al.
Publicado: (2022)

Synthesis, characterization, computational analyses, in silico ADMET studies, and inhibitory action against SARS-CoV-2 main protease (Mpro) of a Schiff base
por: ŞAHİN, Songül, et al.
Publicado: (2022)

Potency, Safety, and Pharmacokinetic Profiles of Potential Inhibitors Targeting SARS-CoV-2 Main Protease
por: Mengist, Hylemariam Mihiretie, et al.
Publicado: (2021)

Identification of novel and potent dual-targeting HDAC1/SPOP inhibitors using structure-based virtual screening, molecular dynamics simulation and evaluation of in vitro and in vivo antitumor activity
por: Yang, Yingxue, et al.
Publicado: (2023)

Screening of potential inhibitors targeting the main protease structure of SARS-CoV-2 via molecular docking
por: Yang, Xinbo, et al.
Publicado: (2022)

Identification of SARS-CoV-2 inhibitors targeting Mpro and PLpro using in-cell-protease assay
por: Narayanan, Anoop, et al.
Publicado: (2022)

Bat coronaviruses related to SARS-CoV-2: what about their 3CL proteases (MPro)?
por: Pavan, Matteo, et al.
Publicado: (2022)

Substitutions in SARS-CoV-2 Mpro Selected by Protease Inhibitor Boceprevir Confer Resistance to Nirmatrelvir
por: Gammeltoft, Karen Anbro, et al.
Publicado: (2023)

Dual-targeting anti-angiogenic cyclic peptides as potential drug leads for cancer therapy
por: Chan, Lai Yue, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_5lfl1dm1maleg19hhcs9ufhlrm